EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/27/2023
Back to search
Official data from USPTO
NEXUSPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
09/27/2023
Trademark type
Combined
Nice classes
42
Filing date
01/17/2020
Registration date
10/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/26/2021
Last transaction
09/27/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-06-00
First use in commerce
2021-06-00
Drawing code
5
Owner type
16
Owner location
Hamilton, NJ
Examiner
CARROLL, DORITT
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "nexuspharma" wherein the term "x" term is comprised of two crossed lines with one of the lines extended a distance further than the other line and both lines intersect, the term "nexus" is in the color green and its font is larger and bolder than the font of the term "pharma" which is in smaller font and not bold and appears in grey.
Holders and representatives
Holders
Genesisnexuspharma LLC
Representatives
Christina E. Brule Heslin Rothenberg Farley & Mesiti P.C.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Consulting services for othersdesigningplanningimplementing preclinical phase II trials in mice for patients suffering from cancer by utlizing patient-derived xenograft mouse models to test the efficacy of cancer drugs in treating cancer patients
Publications
History of USPTO decisions and trademark events.
32 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/27/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/27/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/27/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/26/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/23/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/22/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/20/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/20/2021
IUAF
USE AMENDMENT FILED
08/13/2021
EISU
TEAS STATEMENT OF USE RECEIVED
08/13/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/05/2021
PUBO
PUBLISHED FOR OPPOSITION
01/05/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/16/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/01/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
11/30/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/30/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
11/30/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/30/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
11/30/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
11/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/24/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/01/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/06/2020
GNRT
NON-FINAL ACTION E-MAILED
04/06/2020
CNRT
NON-FINAL ACTION WRITTEN
04/06/2020
DOCK
ASSIGNED TO EXAMINER
04/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/23/2020
NWAP
NEW APPLICATION ENTERED
01/21/2020
Continuous trademark protection
Get notified about every new filing that threatens NEXUSPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.